G

Glenmark Pharmaceuticals Ltd
NSE:GLENMARK

Watchlist Manager
Glenmark Pharmaceuticals Ltd
NSE:GLENMARK
Watchlist
Price: 1 555 INR 0.48% Market Closed
Market Cap: 438.8B INR
Have any thoughts about
Glenmark Pharmaceuticals Ltd?
Write Note

Glenmark Pharmaceuticals Ltd
Common Shares Outstanding

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Glenmark Pharmaceuticals Ltd
Common Shares Outstanding Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Common Shares Outstanding CAGR 3Y CAGR 5Y CAGR 10Y
G
Glenmark Pharmaceuticals Ltd
NSE:GLENMARK
Common Shares Outstanding
â‚ą282.2m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
0%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Common Shares Outstanding
â‚ą833m
CAGR 3-Years
71%
CAGR 5-Years
38%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Common Shares Outstanding
â‚ą807.6m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
0%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Common Shares Outstanding
â‚ą2.4B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
1%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Common Shares Outstanding
â‚ą338.4m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
0%
M
Mankind Pharma Ltd
NSE:MANKIND
Common Shares Outstanding
â‚ą400.6m
CAGR 3-Years
0%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Glenmark Pharmaceuticals Ltd
Glance View

Market Cap
438.8B INR
Industry
Pharmaceuticals

Glenmark Pharmaceuticals Ltd. is a holding company, which engages in the development, manufacture and marketing of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra. The firm is primarily engaged in the business of developing, manufacturing and marketing of pharmaceutical products. The company focuses on manufacturing products across therapeutic areas of respiratory, dermatology and oncology. The company is involved in development of new chemical entities (NCEs) and new biological entities (NBEs). Its business segments include India, North America, Europe and Rest of the world. The company is focused on developing and marketing branded and generic formulations. Its products include FabiFlu, Ryaltris and Remo (Remogliflozin etabonate). Its FabiFlu is an antiviral medication to treat mild to moderate COVID-19. Its Ryaltris is a fixed-dose combination nasal spray of an antihistamine (olopatadine hydrochloride 665 microgram) and a steroid that treats symptoms associated with seasonal, as well as perennial allergic rhinitis. Its Remo is a sodium-glucose transport-2 (SGLT2) inhibitor for the type 2 diabetes.

GLENMARK Intrinsic Value
1 033.31 INR
Overvaluation 34%
Intrinsic Value
Price
G

See Also

What is Glenmark Pharmaceuticals Ltd's Common Shares Outstanding?
Common Shares Outstanding
282.2m INR

Based on the financial report for Jun 30, 2024, Glenmark Pharmaceuticals Ltd's Common Shares Outstanding amounts to 282.2m INR.

What is Glenmark Pharmaceuticals Ltd's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 10Y
0%

Over the last year, the Common Shares Outstanding growth was 0%.

Back to Top